SYK

Stryker
D

SYK

Arincen80/100B

Stryker financials

Yes. Stryker earned 3.62B USD of net income over the last twelve months, 13.8% of its revenue. It made a profit in 41 of its 41 fiscal years since 1985.

Revenue (TTM)
26.30B USD
Net income (TTM)
3.62B USD
Free cash flow (TTM)
4.57B USD
Cash and short-term investments
3.27B USD
Total debt
15.43B USD
Shareholders' equity
23.46B USD

Cash, debt and equity as of 30 Sept 2026.

Stryker earnings

Next earnings · Q4 FY2026
EPS estimate
5.03 USD
Revenue estimate
7.70B USD
Last quarter · Q3 FY2026
EPS3.52Missed -0.8%Revenue6.52BMissed -1.5%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q3 FY20284.32———7.52B———
Q2 FY20284.36———7.56B———
Q1 FY20283.70———6.96B———
Q4 FY20265.03——+12.53%7.70B——+7.34%
Q3 FY20263.553.52-0.85%+10.34%6.62B6.52B-1.47%+7.64%
Q2 FY20263.493.69+5.73%+17.89%6.58B6.59B+0.15%+9.42%
Q1 FY20262.982.60-12.75%-8.45%6.34B6.02B-5.00%+2.63%
Q4 FY20254.404.47+1.59%+11.47%7.12B7.17B+0.65%+11.42%
Q3 FY20253.133.19+1.92%+11.15%6.04B6.06B+0.21%+10.25%
Q2 FY20253.073.13+1.95%+11.39%5.94B6.02B+1.45%+11.07%

Stryker growth and profitability

Full income statement
Revenue (TTM)
26.30B USD
Net income (TTM)
3.62B USD
Gross margin
65.52%
Operating margin
21.25%
Net margin
13.78%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY202525.12B+11.16%3.25B+8.45%63.96%19.47%12.92%6.31B+5.13%
FY202422.60B+10.23%2.99B-5.43%64.37%16.33%13.25%6.01B+18.77%
FY202320.50B+11.11%3.17B+34.22%60.95%20.88%15.44%5.06B+25.86%
FY202218.45B+7.84%2.36B+18.25%59.84%20.24%12.78%4.02B+11.36%
FY202117.11B+19.21%1.99B+24.70%62.60%22.00%11.66%3.61B+17.10%

How Stryker makes its money

MedSurg15.65B 62.3%
Orthopaedics9.47B 37.7%
Revenue25.12B 100.0%
Cost of revenue9.05B 36.0%
Gross profit16.07B 64.0%
Research and development1.58B 6.3%
Selling and administration8.65B 34.4%
Other operating expenses943.00M 3.8%
Operating income4.89B 19.5%
Tax1.27B 5.0%
Other expense375.00M 1.5%
Net income3.25B 12.9%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

Stryker revenue breakdown

By product

FY2025
MedSurg: 62.3%Orthopaedics: 37.7%62.3%MedSurg37.7%Orthopaedics
SegmentRevenueShare of revenueChange on the year
MedSurg15.65B62.3%+15.7%
Orthopaedics9.47B37.7%+4.3%

By region

FY2025
EMEA: 52.1%Asia Pacific: 35.4%Other foreign countries: 12.5%52.1%EMEA35.4%Asia Pacific12.5%Other foreign countries
RegionRevenueShare of revenueChange on the year
EMEA3.18B52.1%+9.8%
Asia Pacific2.16B35.4%+7.1%
Other foreign countries765.00M12.5%+4.1%

Operating and free cash flow

Full cash flow statement
Operating cash flow Free cash flow
Fiscal yearOperating cash flowFree cash flow
FY20255.04B4.28B
FY20244.24B3.49B
FY20233.71B3.14B
FY20222.62B2.04B
FY20213.26B2.74B
FY20203.28B2.79B
FY20192.19B1.54B
FY20182.61B2.04B
FY20171.56B961.00M
FY20161.92B1.43B

Stryker financial health

Full balance sheet
Cash and short-term investments
3.27B USD
Total debt
15.43B USD
Net cash
-12.16B USD
Free cash flow (TTM)
4.57B USD
Current ratio
2.18
Debt to equity
0.66
Piotroski score
9 / 9
Altman Z-score
4.76

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY20254.10B16.36B4.28B
FY20244.49B14.12B3.49B
FY20233.05B13.49B3.14B
FY20221.93B13.53B2.04B
FY20213.02B12.90B2.74B

Assets, liabilities and equity

Total assets Total liabilities Shareholders' equity
Fiscal yearTotal assetsTotal liabilitiesShareholders' equity
FY202547.84B25.42B22.42B
FY202442.97B22.34B20.63B
FY202339.91B21.32B18.59B
FY202236.88B20.27B16.62B
FY202134.63B19.75B14.88B
FY202034.33B21.25B13.08B
FY201930.17B17.36B12.81B
FY201827.23B15.50B11.73B
FY201722.18B12.22B9.97B
FY201620.44B10.89B9.55B

Stryker valuation

Price to earnings ratio (TTM)
33.17
Forward P/E (FY2026)
21.13
Price to sales (TTM)
4.54
Price to book
5.09
EV / EBITDA (TTM)
19.86

Capital structure

Market capitalization
119.33B USD
+
Total debt
15.43B USD
−
Cash and short-term investments
3.27B USD
=
Enterprise value
131.49B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)17.32————
FY2027 (est.)19.2217.32———
FY2026 (est.)21.1319.22———
Now (TTM)33.1719.454.545.0919.86
FY202541.4023.695.355.9923.23
FY202445.8126.556.076.6524.58
FY202335.9124.875.556.1124.56
FY202239.2423.505.015.5625.92
FY202150.5529.145.896.7830.70

Stryker against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Abbott Laboratories, Boston Scientific, Edwards Lifesciences, GE HealthCare Technologies, DexCom, and Zimmer Biomet Holdings, the US Medical - Devices companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Below its median33.2
    31.655.0
  • Gross marginAbove its median64.0%
    59.8%64.4%
    Against its peers: 3 of 7Peers' median 60.9%
  • Operating marginBelow its median19.5%
    16.3%22.0%
    Against its peers: 4 of 7Peers' median 18.9%
  • Net marginAt its median12.9%
    11.7%15.4%
    Against its peers: 5 of 7Peers' median 14.5%
  • Return on equityAt its median14.5%
    13.4%17.0%
    Against its peers: 3 of 7Peers' median 12.2%
  • Free cash flow marginHighest in 5 years17.1%
    11.0%17.1%
    Against its peers: 5 of 7Peers' median 18.1%
  • Revenue growthAbove its median11.2%
    7.8%19.2%
    Against its peers: 4 of 7Peers' median 9.4%
  • EPS growthBelow its median8.2%
    -5.9%33.7%
    Against its peers: 3 of 7Peers' median -7.5%
  • Debt to EBITDABelow its median2.59×
    2.35×3.58×
    Against its peers: 5 of 7Peers' median 1.85×
  • Current ratioAt its median1.89
    1.582.20
    Against its peers: 3 of 7Peers' median 1.75

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Stryker dividends

Annual dividend
3.52 USD
Dividend yield (indicated)
1.12%
Payout ratio
37.25%
Years of dividend growth
27
Frequency
Quarterly
Last payment
0.88 USD
Last ex-dividend date
30 Sept 2026
Last payment date
30 Oct 2026

Dividends per share

Year2025202420232022202120202019201820172016
Dividends per share3.363.203.002.782.522.302.081.881.701.52

Stryker ownership

Institutions
80.95%
Institutional holders
2,341 (-32)
Free float
90.84%

Who owns the shares

Institutions 80.9% Others 19.1%
As of 30 Jun 2026

Shares free to trade

Free float 345.81M shares ·90.8% Closely held 34.88M shares ·9.2%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q3 20260220.00354.90K
Q2 202601430.13K362.82K
Q1 2026019473.43K1.65M
Q4 20250165.14K530.70K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025382.20M382.20M-0.88%
FY2024381.00M385.60M+0.50%
FY2023379.60M383.70M+0.39%
FY2022378.20M382.20M-0.03%
FY2021377.00M382.30M+0.53%

Common questions about Stryker's financials

Source: Financial Modeling Prep